ArticleCase reports in ophthalmological medicine2023
XEN45 Gel Stent Combined with Healaflow Injectable Viscoelastic Implant.
Article in Case reports in ophthalmological medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 6 citations in OpenAlex.
- Effect of Subconjunctival Healaflow in Filtrating Surgery with Preserflo MicroShunt in Primary Open Angle Glaucoma.Journal of clinical medicine · 2025Article
- Reducing Postoperative Needling in XEN63Journal of clinical medicine · 2025Article
- Efficacy and Safety of Ab Externo Open Conjunctiva XENJournal of clinical medicine · 2025Article
- Update on Surgical Techniques Best Practices to Optimize Outcomes Following Gel Stent Implantation.Clinical ophthalmology (Auckland, N.Z.) · 2025Article
- XEN45 Gel Stent Combined with Healaflow Injectable Viscoelastic Implant.Case reports in ophthalmological medicine · 2023Article
- The Road Less Traveled: Ciliary Sulcus Implantation of the Preserflo MicroShunt.Case reports in ophthalmologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To introduce a potential solution for failed glaucoma surgeries by proposing an optional surgical procedure in conjunction with the use of Healaflow (Anteis S.A., Geneva, Switzerland) as a spacer, which may potentially reduce the failure rate. Conclusion: For patients with a history of unsuccessful glaucoma surgeries and who are unsuitable candidates for tube shunt procedures or transscleral diode cyclophotocoagulation, an alternative option involves implanting the XEN45 stent in the inferior nasal region in conjunction with the use of subconjunctival Healaflow. This combined approach may provide a potential solution for managing glaucoma in these patients.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.